Bavarian will use own money to start RSV trials, but is still seeking a partner

After several discussions with the FDA, Bavarian Nordic has finally finished designing the study of its RSV vaccine and will start a 12,000 person phase III study in 2021.

Photo: PR / Bavarian Nordic

As the end of the year approaches, Bavarian Nordic has started to look towards 2020, and has revealed two central points of next year's work: the purchase of two new vaccines from Glaxosmithkline and a timeline for the company's large phase III test of a vaccine against airway virus RSV.

The timeline for the RSV vaccine has been particularly long-awaited, as Bavarian's negotiations with the American medicine authorities over the design of the study have dragged out, and the final agreement has come much later than expected.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs